BioNxt Solutions Inc.
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheum… Read more
BioNxt Solutions Inc. (BNXTF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.244x
Based on the latest financial reports, BioNxt Solutions Inc. (BNXTF) has a cash flow conversion efficiency ratio of 0.244x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.03 Million) by net assets ($-8.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioNxt Solutions Inc. - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how BioNxt Solutions Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BioNxt Solutions Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioNxt Solutions Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
5paisa Capital Ltd
NSE:5PAISA
|
-0.100x |
|
PharmGen Science Inc
KO:004720
|
0.008x |
|
Kron Telekomunikasyon Hizmetleri AS
IS:KRONT
|
0.156x |
|
Shihlin Development Company Limited
TWO:5324
|
-0.058x |
|
Ditas Dogan Yedek Parca Imalat ve Teknik AS
IS:DITAS
|
-0.443x |
|
H&R GmbH & Co. KGaA
XETRA:2HRA
|
0.054x |
|
Vittia Fertilizantes
SA:VITT3
|
0.172x |
|
Trk Corp
TW:1432
|
0.076x |
Annual Cash Flow Conversion Efficiency for BioNxt Solutions Inc. (2018–2024)
The table below shows the annual cash flow conversion efficiency of BioNxt Solutions Inc. from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-7.86 Million | $-3.03 Million | 0.386x | -60.55% |
| 2023-12-31 | $-5.28 Million | $-5.17 Million | 0.978x | -35.17% |
| 2022-12-31 | $-4.13 Million | $-6.23 Million | 1.509x | +120.72% |
| 2021-12-31 | $1.67 Million | $-12.16 Million | -7.284x | -185.93% |
| 2020-12-31 | $4.01 Million | $-10.20 Million | -2.548x | -336.56% |
| 2019-12-31 | $6.32 Million | $-3.69 Million | -0.584x | -627.21% |
| 2018-12-31 | $7.76 Million | $-622.91K | -0.080x | -- |